Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Citius Pharmaceuticals Inc CTXR

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company’s late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.


NDAQ:CTXR - Post by User

User Avatar Image
(0)
•••
  • FrugalNorwegianX
Post by FrugalNorwegianon May 12, 2021 12:52pm
249 Views
Post# 33183430

New website with deep DD on CTXR 👇

New website with deep DD on CTXR 👇New site with Deep DD on CTXR: Frugalnorwegian.com/ctxr

- All information on 1 page
- Catalyst countdown timer
- Several videos to watch
- Provides a high level summary, and goes deep into the clinical trial success chances
<< Previous
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities